Gilead Sciences has reported positive 24-week data from its Switching boosted PI to Rilpivirine In Combination with Truvada as a Single Tablet Regimen (SPIRIT) trial of Complera.

The Phase 3 clinical trial identified that once-daily single tablet regimen Complera maintains HIV suppression among patients switching from a multi-pill regimen containing ritonavir-boosted protease inhibitor regimens.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The SPIRIT study principal investigator and the Northwestern University Feinberg School of Medicine professor of medicine Frank Palella said that since its approval for patients new to HIV therapy, the daily single tablet regimen of Complera has become an important addition to the list of treatment options available for these patients.

"In this current study, data demonstrate Complera has the potential to help a broader range of HIV-infected patients," Palella added.

The study met its 24-week primary endpoint, which found that switching to Complera was non-inferior to remaining on a ritonavir-boosted protease inhibitor regimen.

See Also:

At 24 weeks of treatment, 94% of patients (n=297/317) who switched to Complera maintained HIV RNA (viral load) levels less than 50 copies/mL compared to 90% of patients (n=143/159) who remained on a regimen containing a ritonavir-boosted protease inhibitor-based regimen.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Fewer patients taking Complera experienced virologic failure compared to those taking a protease-based regimen and the patients in the Complera arm demonstrated statistically significant improvements in total cholesterol levels.

Gilead is even evaluating Complera in two post-marketing studies, Phase 3b head-to-head trial comparing Complera to Atripla among patients who are new to therapy and a Phase 2b open-label pilot study evaluating the efficacy and safety of switching virologically suppressed Atripla patients to Complera.